Presented by Proffe Invest: Michael Proffe has spent 30+ years spotting powerful market trends, and he turned $30,000 into $3 million with his trend-following strategy. Now he's named 3 stocks he believes could power the next phase of the AI boom. Get the free report revealing all three →
🔥 Good Morning from Top Tickers
🔥 This Engineering Stock Just Jumped 10% Premarket
The chip trade is splitting again this morning. The sector’s biggest name is sinking as fresh questions about its CEO land on the board’s desk, while a rival is climbing on an upgrade that frames the turmoil as its opening.
Away from semis, earnings are sorting winners from losers. An engineering and consulting firm is jumping on a quarter that cleared the bar, and an agricultural name is sliding after revenue came up well short.
🤝 Sponsored By Proffe Invest
MICHAEL PROFFE HAS SPENT 30+ YEARS BEATING THE MARKET AND IDENTIFYING POWERFUL MARKET TRENDS.
He turned $30,000 into 3 million with his trend-following strategy.
Now, he’s zeroed in on 3 stocks he believes could be major beneficiaries of AI’s next phase—and they’re probably not the names you’re expecting.
He reveals all three in this FREE report.
🚀 Pre-Market Movers
The Biggest Gainers, Ranked
Tetra Tech (TTEK): +10%
The consulting and engineering services provider is jumping after fiscal fourth-quarter earnings edged past expectations, with revenue landing in line. Shares dropped about 7% in the prior session, so a clean print is enough to bring buyers back this morning.
Advanced Micro Devices (AMD): +2%
William Blair upgraded the chipmaker to Outperform from Market Perform, arguing its Instinct AI accelerators are poised to take share while its two biggest rivals stumble. One is dealing with delays and supply shortages on a next-generation processor, and the other is caught up in a leadership and regulatory mess. The firm sees that opening as something that could benefit AMD over several years, not just this morning.
100 side hustles. Zero brainstorming.
Ready to stop scrolling job boards and start building something of your own?
The Hustle's free "Side Hustle Ideas Database" uncovers 100 unconventional, actually-actionable ways to earn on the side.
Inside you'll find:
A curated list of 100 real side hustle ideas spanning e-commerce, services, content, and weird corners of the internet most people never think to look
Opportunities at every level, whether you have 5 hours a week or 50, zero capital or a small runway
Offbeat, under-the-radar ideas you won't find in generic "how to make money" listicles
Subscribe for free today and get instant access. Your next income stream is one click away.
📉 Pre-Market Movers
The Biggest Losers, Ranked
Corteva (CTVA): -9%
The agricultural chemical and seed company is sliding after third-quarter revenue came in well short of what analysts expected. A top-line miss this wide leaves investors guessing about demand, and the stock is repricing before the bell.
Nvidia (NVDA): -7%
The AI chip leader is tumbling again after The New York Times (NYT) reported that CEO Jensen Huang had a second affair, this time with a company vice president who reports to him. The board met Wednesday to discuss his future. With the top job now an open question, investors are pricing in leadership uncertainty on top of an already rough stretch.
🤝 Sponsored By Proffe Invest
MICHAEL PROFFE HAS SPENT 30+ YEARS BEATING THE MARKET AND IDENTIFYING POWERFUL MARKET TRENDS.
He turned $30,000 into 3 million with his trend-following strategy.
Now, he’s zeroed in on 3 stocks he believes could be major beneficiaries of AI’s next phase—and they’re probably not the names you’re expecting.
He reveals all three in this FREE report.
👀 What We’re Watching
Here’s One Ticker That’s Trending Today
Capricor Therapeutics (CAPR)
The FDA is due to rule by November 22 on deramiocel, Capricor’s cell therapy for Duchenne muscular dystrophy, and retail traders are counting down. StockTwits message volume has been running at extremely high levels with sentiment reading extremely bullish, as posters parse management’s comments for labeling hints and debate how much rejection risk is left.
Management reaffirmed its confidence in the data on Tuesday’s earnings call, but an FDA advisory panel voted against the drug in July, and the stock is still down about 60% this year. The decision could be the event that either rewards the holdouts or confirms why the stock fell so far.
✌️That’s it for today.